These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 18474152)

  • 1. Effectiveness of assigning BI-RADS category-3 to breast lesion with respect to follow-up.
    Masroor I
    J Coll Physicians Surg Pak; 2008 Apr; 18(4):209-12. PubMed ID: 18474152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of benignity or malignancy of a lesion using BI-RADS.
    Masroor I
    J Coll Physicians Surg Pak; 2005 Nov; 15(11):686-8. PubMed ID: 16300702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Revisiting the mammographic follow-up of BI-RADS category 3 lesions.
    Varas X; Leborgne JH; Leborgne F; Mezzera J; Jaumandreu S; Leborgne F
    AJR Am J Roentgenol; 2002 Sep; 179(3):691-5. PubMed ID: 12185047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BI-RADS categorization as a predictor of malignancy.
    Orel SG; Kay N; Reynolds C; Sullivan DC
    Radiology; 1999 Jun; 211(3):845-50. PubMed ID: 10352614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term follow-up results in 795 nonpalpable probably benign lesions detected at screening mammography.
    Vizcaíno I; Gadea L; Andreo L; Salas D; Ruiz-Perales F; Cuevas D; Herranz C; Bueno F;
    Radiology; 2001 May; 219(2):475-83. PubMed ID: 11323475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient compliance and diagnostic yield of 18-month unilateral follow-up in surveillance of probably benign mammographic lesions.
    Chung CS; Giess CS; Gombos EC; Frost EP; Yeh ED; Raza S; Birdwell RL
    AJR Am J Roentgenol; 2014 Apr; 202(4):922-7. PubMed ID: 24660725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of BI-RADS 3-probably benign category in the American College of Radiology Imaging Network Digital Mammographic Imaging Screening Trial.
    Baum JK; Hanna LG; Acharyya S; Mahoney MC; Conant EF; Bassett LW; Pisano ED
    Radiology; 2011 Jul; 260(1):61-7. PubMed ID: 21502382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal measurement of clinical mammographic breast density to improve estimation of breast cancer risk.
    Kerlikowske K; Ichikawa L; Miglioretti DL; Buist DS; Vacek PM; Smith-Bindman R; Yankaskas B; Carney PA; Ballard-Barbash R;
    J Natl Cancer Inst; 2007 Mar; 99(5):386-95. PubMed ID: 17341730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reassessment and Follow-Up Results of BI-RADS Category 3 Lesions Detected on Screening Breast Ultrasound.
    Chae EY; Cha JH; Shin HJ; Choi WJ; Kim HH
    AJR Am J Roentgenol; 2016 Mar; 206(3):666-72. PubMed ID: 26901026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamic contrast-enhanced MR imaging in screening detected microcalcification lesions of the breast: is there any value?
    Uematsu T; Yuen S; Kasami M; Uchida Y
    Breast Cancer Res Treat; 2007 Jul; 103(3):269-81. PubMed ID: 17063274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The breast imaging reporting and data system: positive predictive value of mammographic features and final assessment categories.
    Liberman L; Abramson AF; Squires FB; Glassman JR; Morris EA; Dershaw DD
    AJR Am J Roentgenol; 1998 Jul; 171(1):35-40. PubMed ID: 9648759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histologic work-up of non-palpable breast lesions classified as probably benign at initial mammography and/or ultrasound (BI-RADS category 3).
    Gruber R; Jaromi S; Rudas M; Pfarl G; Riedl CC; Flöry D; Graf O; Sickles EA; Helbich TH
    Eur J Radiol; 2013 Mar; 82(3):398-403. PubMed ID: 22429299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Computer-aided classification of BI-RADS category 3 breast lesions.
    Buchbinder SS; Leichter IS; Lederman RB; Novak B; Bamberger PN; Sklair-Levy M; Yarmish G; Fields SI
    Radiology; 2004 Mar; 230(3):820-3. PubMed ID: 14739315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Stereotactic Mammotome breast biopsy: routine clinical experience and correlation with BI-RADS--classification and histopathology].
    Michel SC; Löw R; Singer G; Otto R; Hohl M; Kubik RA
    Praxis (Bern 1994); 2007 Sep; 96(39):1459-74. PubMed ID: 17966279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted Ultrasound of an Indeterminate Breast Lesion on Mammography: When Does It Influence Management?
    Sohail S; Masroor I; Afzal S
    J Coll Physicians Surg Pak; 2015 Aug; 25(8):564-7. PubMed ID: 26305300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The value of breast MRI for BI-RADS category 4B mammographic microcalcification: based on the 5
    Eun NL; Son EJ; Gweon HM; Youk JH; Kim JA
    Clin Radiol; 2018 Aug; 73(8):750-755. PubMed ID: 29853301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of BI-RADS category 4 lesions detected with screening mammography and screening US: utility of MR imaging.
    Strobel K; Schrading S; Hansen NL; Barabasch A; Kuhl CK
    Radiology; 2015 Feb; 274(2):343-51. PubMed ID: 25271857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Positive predictive value of breast cancer in the lesions categorized as BI-RADS category 5.
    Wiratkapun C; Lertsithichai P; Wibulpholprasert B
    J Med Assoc Thai; 2006 Aug; 89(8):1253-9. PubMed ID: 17048437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BI-RADS 3, 4, and 5 lesions: value of US in management--follow-up and outcome.
    Raza S; Chikarmane SA; Neilsen SS; Zorn LM; Birdwell RL
    Radiology; 2008 Sep; 248(3):773-81. PubMed ID: 18647850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer Yield and Patterns of Follow-up for BI-RADS Category 3 after Screening Mammography Recall in the National Mammography Database.
    Berg WA; Berg JM; Sickles EA; Burnside ES; Zuley ML; Rosenberg RD; Lee CS
    Radiology; 2020 Jul; 296(1):32-41. PubMed ID: 32427557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.